Supernus, Inc.

Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.